Marina Udier, Nouscom CEO
November 14, 2023 01:00 AM EST
Financing
Startups

Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Kyle LaHucik

Senior Reporter

Basel-based biotech Nous­com has raised €67.5 mil­lion ($72.2 mil­lion) to bankroll its can­cer vac­cines as the eight-year-old com­pa­ny looks to cap­i­tal­ize on mo­men­tum in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times